Targeted drug trial aims to extend remission for Tough-to-Treat lung cancer
NCT ID NCT07235306
Summary
This study is testing whether adding the targeted drug ensartinib after standard chemoradiation can better control advanced, inoperable lung cancer in patients with a specific genetic change (ALK mutation). It will involve about 45 patients who have completed initial treatment without their cancer getting worse. Participants will be randomly assigned to receive either ensartinib or a placebo pill to compare how long the cancer stays under control and to monitor safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMORADIOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.